KORU Medical names Adam Kalbermatten as chief commercial officer

KORU Medical Systems (NASDAQ: KRMD) appointed Adam Kalbermatten as chief commercial officer, effective July 28, 2025, according to a company statement.

Kalbermatten will oversee the medical device company's global commercial strategy, including marketing, sales, market access, and pharmaceutical customer engagement. He brings over 20 years of commercial leadership experience in the medical device and pharmaceutical industries.

Kalbermatten joins KORU Medical from Becton Dickinson, where he served as vice president and general manager of advanced drug delivery systems. He previously served as chief executive officer of ZebraSci, a provider of analytical and drug device combination product development services, which was acquired by Becton Dickinson. He also held leadership roles at Terumo Medical Corporation.

Kalbermatten holds a bachelor's degree in mechanical engineering and a master's degree in engineering management from Stevens Institute of Technology, and an MBA with concentrations in finance and healthcare from Columbia Business School.

"Adam is a highly accomplished commercial leader with a strong presence in the market and deep customer relationships that have driven tangible business growth," said Linda Tharby, president and CEO of KORU Medical.

KORU Medical develops and manufactures subcutaneous infusion solutions, including the FREEDOM Syringe Infusion System, which received its first FDA clearance in 1994.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Cronos Group extends cannabis acquisition deadline to October 2026
• Elastic launches serverless vector database on its cloud platform